330 related articles for article (PubMed ID: 31085240)
1. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
Wu H; Liu G; He Y; Da J; Xie B
Eur J Pharmacol; 2019 Sep; 858():172393. PubMed ID: 31085240
[TBL] [Abstract][Full Text] [Related]
2. Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury.
Zhu JB; Xu S; Li J; Song J; Luo B; Song YP; Zhang ZH; Chen YH; Xie DD; Yu DX; Xu DX
Eur J Pharmacol; 2018 Nov; 838():60-68. PubMed ID: 30196109
[TBL] [Abstract][Full Text] [Related]
3. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
4. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
[TBL] [Abstract][Full Text] [Related]
5. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
[TBL] [Abstract][Full Text] [Related]
6. Protection by dimethyl fumarate against diabetic cardiomyopathy in type 1 diabetic mice likely via activation of nuclear factor erythroid-2 related factor 2.
Hu X; Rajesh M; Zhang J; Zhou S; Wang S; Sun J; Tan Y; Zheng Y; Cai L
Toxicol Lett; 2018 May; 287():131-141. PubMed ID: 29408448
[TBL] [Abstract][Full Text] [Related]
7. Zinc Prevents the Development of Diabetic Cardiomyopathy in db/db Mice.
Wang S; Wang B; Wang Y; Tong Q; Liu Q; Sun J; Zheng Y; Cai L
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272348
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
[TBL] [Abstract][Full Text] [Related]
9. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
[TBL] [Abstract][Full Text] [Related]
10. Obeticholic Acid Protects against Lipopolysaccharide-Induced Fetal Death and Intrauterine Growth Restriction through Its Anti-Inflammatory Activity.
Chen YH; Hu XG; Zhou Y; Yu Z; Fu L; Zhang GB; Bo QL; Wang H; Zhang C; Xu DX
J Immunol; 2016 Dec; 197(12):4762-4770. PubMed ID: 27821667
[TBL] [Abstract][Full Text] [Related]
11. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
Wang XX; Wang D; Luo Y; Myakala K; Dobrinskikh E; Rosenberg AZ; Levi J; Kopp JB; Field A; Hill A; Lucia S; Qiu L; Jiang T; Peng Y; Orlicky D; Garcia G; Herman-Edelstein M; D'Agati V; Henriksen K; Adorini L; Pruzanski M; Xie C; Krausz KW; Gonzalez FJ; Ranjit S; Dvornikov A; Gratton E; Levi M
J Am Soc Nephrol; 2018 Jan; 29(1):118-137. PubMed ID: 29089371
[TBL] [Abstract][Full Text] [Related]
12. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
[TBL] [Abstract][Full Text] [Related]
13. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
Fan YY; Ding W; Zhang C; Fu L; Xu DX; Chen X
Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
[TBL] [Abstract][Full Text] [Related]
14. Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis.
Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corcetto F; Corno C; Maneschi E; Pini A; Adorini L; Vannelli GB; Maggi M; Vignozzi L
J Steroid Biochem Mol Biol; 2017 Apr; 168():26-37. PubMed ID: 28115235
[TBL] [Abstract][Full Text] [Related]
15. Obeticholic acid alleviate lipopolysaccharide-induced acute lung injury via its anti-inflammatory effects in mice.
Fei J; Fu L; Hu B; Chen YH; Zhao H; Xu DX; Li JB
Int Immunopharmacol; 2019 Jan; 66():177-184. PubMed ID: 30468885
[TBL] [Abstract][Full Text] [Related]
16. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465
[TBL] [Abstract][Full Text] [Related]
17. Guan Xin Dan Shen formulation protects
Zhang B; Zhang CY; Zhang XL; Sun GB; Sun XB
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036388
[TBL] [Abstract][Full Text] [Related]
18. Bile Acids and Farnesoid X Receptor: Novel Target for the Treatment of Diabetic Cardiomyopathy.
Li C; Li Y; Gai Z
Curr Protein Pept Sci; 2019; 20(10):976-983. PubMed ID: 31362653
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
20. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
Liu SY; Huang CC; Yang YY; Huang SF; Lee TY; Li TH; Hou MC; Lin HC
PLoS One; 2022; 17(12):e0276717. PubMed ID: 36490253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
